Control of Metastatic Tumor Growth in a Patient with Sporadic Metastatic Malignant Peripheral Nerve Sheath Tumor (sMPNST) Using the Hope Protocol, an Alternative Treatment Regimen for Cancer


Integrative cancer therapy
Repurposed drugs
DeltaRex-G gene therapy


How to Cite

Gordon E, Dang J, Angel NL, Brigham DA, Ostendorf L, Jafari O, Chawla SP, Hall FL. Control of Metastatic Tumor Growth in a Patient with Sporadic Metastatic Malignant Peripheral Nerve Sheath Tumor (sMPNST) Using the Hope Protocol, an Alternative Treatment Regimen for Cancer. Integr J Med Sci [Internet]. 2021 Mar. 3 [cited 2024 Jun. 15];8. Available from:


Metastatic sporadic malignant peripheral nerve sheath tumor (sMPNST) is associated with only 17% five-year survival rate using standard chemotherapy and there are no 10-year survival reports with the exception of a case report wherein a patient with metastatic sMPNST is still alive with no active disease and on no further cancer therapy, >12 years from DeltaRex-G treatment initiation. In this case report, we describe an interim alternative treatment regimen designed and used by a patient with metastatic sMPNST, while awaiting the return, GMP bioproduction, and QC certification of DeltaRex-G as a potential treatment option. We report on the successful control of metastatic tumor growth over a one-year treatment period using the Hope Protocol consisting of artemisinin, curcumin, cannabis oil, disulfiram, fenbendazole, mebendazole, albendazole, atorvastatin, doxycycline, vitamin C, vitamin E, a plant-based diet, sans refined sugar, yoga, acupuncture, meditation, exercise and hot sauna, and we discuss their biochemical mechanisms of action.


Hwang IK, Hahn SM, Kim HS, Kim SK, Kim HS, Shin KH, et al. Outcomes of treatment for malignant peripheral nerve sheath tumors: Different clinical features associated with neurofibromatosis Type 1. Cancer Res Treat. 2017 Jul;49(3):717-726.

Kim S, Federman N, Gordon EM, Hall FL, Chawla SP. Rexin-G®, a tumor-targeted retrovector for malignant peripheral nerve sheath tumor: A case report. Mol Clin Oncol. 2017 Jun;6(6):861-865.

Seltzer ES, Watters AK, MacKenzie D, Granat LM, Zhang D. Cannabidiol (CBD) as a promising anti-cancer drug. Cancers (Basel). 2020 Oct 30;12(11):3203.

World Cancer Research Fund/American Institute for Cancer Research. Diet, Nutrition, Physical Activity and Cancer: a Global Perspective. World Cancer Research Fund. 2018. [Accessed 2021 Feb 6]. Available from:

Nechuta SJ, Caan BJ, Chen WY, Lu W, Chen Z, Kwan ML, et al. Soy food intake after diagnosis of breast cancer and survival: An in-depth analysis of combined evidence from cohort studies of US and Chinese women. Am J Clin Nutr. 2012 Jul;96(1):123-32.

Madigan M, Karhu E. The role of plant-based nutrition in cancer prevention. J Unexplored Medical Data. 2018;3. [Accessed 2021 Febr 6]. Available from:

Duan W, Shen X, Lei J, Xu Q, Yu Y, Li R, et al. Hyperglycemia, a neglected factor during cancer progression. Biomed Res Int. 2014;2014:461917.

Liu H, Heaney AP. Refined fructose and cancer. Expert Opin Ther Targets. 2011 Sep;15 (9):1049-59.

Fatehi Hassanabad A. Current perspectives on statins as potential anti-cancer therapeutics: clinical outcomes and underlying molecular mechanisms. Transl Lung Cancer Res. 2019 Oct;8(5):692-699.

Meraz-Torres F, Plöger S, Garbe C, Niessner H, Sinnberg T. Disulfiram as a therapeutic agent for metastatic malignant melanoma-Old myth or new logos? Cancers (Basel). 2020 Nov 27;12(12):3538.

Duan Q, Liu Y, Rockwell S. Fenbendazole as a potential anticancer drug. Anticancer Res. 2013;33:355-362.

Dogra N, Kumar A, Mukhopadhyay T. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Sci Rep. 2018 Aug 9;8(1):11926.

Zhang Z, Zhou L, Xie N, Nice EC, Zhang T, Cui Y, et al. Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduct Target Ther. 2020 Jul 2;5(1):113.

Ghasemi F, Black M, Vizeacoumar F, Pinto N, Ruicci KM, Le CCSH, et al. Repurposing Albendazole: new potential as a chemotherapeutic agent with preferential activity against HPV-negative head and neck squamous cell cancer. Oncotarget. 2017 Apr 20;8(42):71512-71519.

Zhang L, Xu L, Zhang F, Vlashi E. Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer. Cell Cycle. 2017 Apr 18;16(8):737-745.

Dijk SN, Protasoni M, Elpidorou M, Kroon AM, Taanman J-W. Mitochondriaas target to inhibit proliferation and induce apoptosis of cancer cells: the effects of doxycycline and gemcitabine. Sci Rep. 2020 Mar 9;10(1):4363.

Lai HC, Singh NP, Sasaki T. Development of artemisinin compounds for cancer treatment. Invest New Drugs. 2013 Feb;31(1):230-46.

Waseem Y, Hasan CA, Ahmed F. Artemisinin: A promising adjunct for cancer therapy. Cureus. 2018 Nov 23;10(11):e3628.

Tan BL, Norhaizan ME. Curcumin combination chemotherapy: The implication and efficacy in cancer. Molecules. 2019 Jul 10;24(14):2527.

Vissers MCM, Das AB. Potential mechanisms of action for vitamin C inc: Reviewing the evidence. Front Physiol. 2018 Jul 3;9:809.

Jiang Q. Natural Forms of Vitamin E as effective agents for cancer prevention and therapy. Adv Nutr. 2017 Nov 15;8(6):850-867.

Rao RM, Amritanshu R, Vinutha HT, Vaishnaruby S, Deepashree S, Megha M, et al. Role of yoga in cancer patients: Expectations, benefits, and risks: A review. Indian J Palliat Care. 2017 Jul-Sep;23(3):225-230.

Beri K. The impact of the “Yogic Lifestyle” on cancer prognosis and survival: Can we target cancer stem cells with yoga? Int J Yoga. May-Aug 2017;10(2):95-98.

Pascoe MC, Thompson DR, Jenkins ZM, Ski CF. Mindfulness mediates the physiological markers of stress: Systematic review and meta-analysis. J Psychiatr Res. 2017 Dec;95:156-178.

Mavoungou E, Bouyou‐Akotet MK, Kremsner PG. Effects of prolactin and cortisol on natural killer (NK) cell surface expression and function of human natural cytotoxicity receptors (NKp46, NKp44 and NKp30). Clin Exp Immunol. 2005 Feb;139(2):287-96.

Djiogue S, Nwabo Kamdje AH, Vecchio L, Kipanyula MJ, Farahna M, Aldebasi Y, et al. Insulin resistance and cancer: the role of insulin and IGFs. Endocr Relat Cancer. 2013 Jan 7;20(1):R1-R17.

Ngamkham S, Holden JE, Smith EL. A systematic review: Mindfulness intervention forcancer-related pain. Asia Pac J Oncol Nurs. Apr-Jun 2019;6(2):161-169.

Hojman P, Gehl J, Christensen JF, Pedersen BK. Molecular mechanisms linking exercise to cancer prevention and treatment. Cell Metab. 2018 Jan 9;27(1):10-21.

Ishibashi J, Yamashita K,Ishikawa T, et al. The effects inhibiting the proliferation of cancer cells by far-infrared radiation (FIR) are controlled by the basal expression level of heat shock protein (HSP) 70A. Med Oncol. 2008;25(2):229-37.

Zia FZ, Olaku O, Bao T, Berger A, Deng G, Fan AY, et al. The National Cancer Institute’s Conference on Acupuncture for Symptom Management in Oncology: State of the Science, Evidence, and Research Gaps. J Natl Cancer Inst Monogr. 2017 Nov 1;2017(52):lgx005.

Al-Shihabi A, Chawla SP, Hall FL, Gordon EM. Exploiting oncogenic drivers along the CCNG1 pathway for cancer therapy and gene therapy. Mol Ther Oncolytics. 2018 Dec 12;11:122-126.

Liu S, Chawla S, Bruckner H, Morse MA, Federman N, Srikureja A, et al. Long term survival following precision tumor-targeted gene delivery to advanced chemotherapy-resistant malignancies: an academic milestone. Clin Oncol. 2021. [Accessed 2021 Febr 6]. Available from:

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2021 Gordon EM et al.


Download data is not yet available.


Metrics Loading ...